In Iran, maldistribution of specialists across provinces is evident and represents a serious challenge, mirroring global ...

The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

This was a study led by Dr. Pallawi Torka from Memorial Sloan Kettering that we participated in, where they performed as a ...

Non-invasive recordings using brain electrophysiology provide credible insights into decline in neuronal functioning with age. New approaches are required to translate these results into compelling ...

UNIONDALE, NY / ACCESS Newswire / December 8, 2025 / Marquis Who’s Who, the trusted biographical authority documenting ...